eIF4A inhibition: ready for primetime?

Oncotarget. 2018 Oct 30;9(85):35515-35516. doi: 10.18632/oncotarget.26268.

Authors

Tyler A Cunningham¹, Eli Chapman¹, Jonathan H Schatz¹

Affiliation

¹ Jonathan H. Schatz: Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA; Division of Hematology, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.

No abstract available

Keywords: cap-dependent translation; drug discovery; eIF4A; experimental therapeutics; signaling.

Publication types

Editorial